Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-401-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.94 million
Profitability
Miscellaneous
Employees133
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.10. The company earned $2.33 million during the quarter, compared to analysts' expectations of $6.88 million. Editas Medicine had a negative return on equity of 47.46% and a negative net margin of 412.70%. The business's revenue for the quarter was down 68.4% compared to the same quarter last year. During the same period last year, the company earned ($0.82) earnings per share. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
10 brokerages have issued twelve-month price targets for Editas Medicine's shares. Their forecasts range from $29.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price. View Analyst Price Targets for Editas Medicine.
What is the consensus analysts' recommendation for Editas Medicine?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.
What are Wall Street analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019)
- 2. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (5/10/2019)
Has Editas Medicine been receiving favorable news coverage?
Media headlines about EDIT stock have trended negative on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Editas Medicine earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Editas Medicine.
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Repligen (RGEN), argenx (ARGX), Moderna (MRNA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX) and Coherus Biosciences (CHRS).
What other stocks do shareholders of Editas Medicine own?
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Dr. Charles Albright, Chief Scientific Officer (Age 61)
- Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)
- Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
- Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
- Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member
When did Editas Medicine IPO?
(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who are Editas Medicine's major shareholders?
Editas Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.85%), Vanguard Group Inc. (8.67%), BlackRock Inc. (7.82%), Nikko Asset Management Americas Inc. (6.32%), Sumitomo Mitsui Trust Holdings Inc. (3.08%) and Morgan Stanley (1.72%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.
Which institutional investors are selling Editas Medicine stock?
EDIT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Ontario Teachers Pension Plan Board, Global Thematic Partners LLC, Bank of America Corp DE, Nisa Investment Advisors LLC, Parametric Portfolio Associates LLC, GSA Capital Partners LLP and Elmwood Wealth Management Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.
Which institutional investors are buying Editas Medicine stock?
EDIT stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., ARK Investment Management LLC, D. E. Shaw & Co. Inc., Nuveen Asset Management LLC, Balyasny Asset Management LLC and BlackRock Inc.. View Insider Buying and Selling for Editas Medicine.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $25.64.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.27 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine.
What is Editas Medicine's official website?
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
